Loading clinical trials...
Loading clinical trials...
A Phase II Evaluation of SU11248 (Sunitinib Malate) (NSC #736511) in the Treatment of Persistent or Recurrent Clear Cell Ovarian Carcinoma
Conditions
Interventions
Laboratory Biomarker Analysis
Sunitinib Malate
Locations
97
United States
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California, United States
John Muir Medical Center-Concord Campus
Concord, California, United States
Los Angeles County-USC Medical Center
Los Angeles, California, United States
USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States
UCSF Medical Center-Mount Zion
San Francisco, California, United States
Start Date
April 19, 2010
Primary Completion Date
May 1, 2014
Completion Date
February 9, 2019
Last Updated
February 19, 2020
NCT05039801
NCT04550494
NCT07144826
NCT06855706
NCT06295965
NCT04919629
Lead Sponsor
National Cancer Institute (NCI)
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions